PuSH - Publication Server of Helmholtz Zentrum München: Metformin causes a futile intestinal-hepatic cycle which increase energy expenditure and slows down development of a type 2 diabetes-like state.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Schommers, P.* ; Thurau, A.* ; Bultmann-Mellin, I.* ; Guschlbauer, M.* ; Klatt, A.R.* ; Rozman, J. ; Klingenspor, M. ; Hrabě de Angelis, M. ; Alber, J.* ; Gründemann, D.* ; Sterner-Kock, A.* ; Wiesner, R.J.*

Metformin causes a futile intestinal-hepatic cycle which increase energy expenditure and slows down development of a type 2 diabetes-like state.

Mol. Metab. 6, 737-747 (2017)

Publ. Version/Full Text

Postprint

Research data

DOI

	Open Access Gold

Abstract
Metrics
Extra information

Objective Metformin, the first line drug for treatment of type 2 diabetes, suppresses hepatic gluconeogenesis and reduces body weight in patients, the latter by an unknown mechanism. Methods Mice on a high fat diet were continuously fed metformin in a therapeutically relevant dose, mimicking a retarded formulation. Results Feeding metformin in pharmacologically relevant doses to mice on a high fat diet normalized HbA1c levels and ameliorated glucose tolerance, as expected, but also considerably slowed down weight gain. This was due to increased energy expenditure, since food intake was unchanged and locomotor activity was even decreased. Metformin caused lactate accumulation in the intestinal wall and in portal venous blood but not in peripheral blood or the liver. Increased conversion of glucose-1-¹³C to glucose-1,6-¹³C under metformin strongly supports a futile cycle of lactic acid production in the intestinal wall, and usage of the produced lactate for gluconeogenesis in liver. Conclusions The reported glucose–lactate–glucose cycle is a highly energy consuming process, explaining the beneficial effects of metformin given continuously on the development of a type 2 diabetic-like state in our mice.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

6.799

1.528